Advanced Bifurcation Systems

Executive Summary

Advanced Bifurcation Systems (ABS) is a private medical device company pioneering a novel platform to treat coronary bifurcation lesions, a complex and prevalent condition in interventional cardiology. Its FDA Breakthrough Device Designated system simplifies the stenting procedure, reduces procedural time, and improves long-term patient outcomes compared to current techniques. By addressing a significant unmet need, ABS's technology has the potential to become the new standard of care in percutaneous coronary interventions for bifurcation lesions. The company, based in the San Francisco Bay Area and founded in 2014, is advancing through clinical trials and preparing for regulatory submission. With a strong intellectual property portfolio and positive early clinical data, ABS is positioned to capture a substantial share of the global coronary stent market, which is valued at over $8 billion annually. The combination of a validated clinical need, a differentiated product, and regulatory support makes ABS an attractive investment opportunity in the medical device space.

Upcoming Catalysts (preview)

• Q2 2026Pivotal Trial Enrollment Completion80% success
• Q3 2026FDA Premarket Approval (PMA) Submission65% success
• Q4 2026Strategic Partnership with Major Cardiovascular Company50% success